Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
2(20%)
Results Posted
20%(1 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_4
3
30%
Ph phase_2
1
10%
Ph early_phase_1
2
20%
Ph phase_3
1
10%
Ph not_applicable
1
10%
Ph phase_1
2
20%

Phase Distribution

4

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution10 total trials
Early Phase 1First-in-human
2(20.0%)
Phase 1Safety & dosage
2(20.0%)
Phase 2Efficacy & side effects
1(10.0%)
Phase 3Large-scale testing
1(10.0%)
Phase 4Post-market surveillance
3(30.0%)
N/ANon-phased studies
1(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

2

trials recruiting

Total Trials

10

all time

Status Distribution
Active(3)
Completed(5)
Terminated(1)
Other(1)

Detailed Status

Completed5
Recruiting2
Terminated1
unknown1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
2
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (20.0%)
Phase 12 (20.0%)
Phase 21 (10.0%)
Phase 31 (10.0%)
Phase 43 (30.0%)
N/A1 (10.0%)

Trials by Status

completed550%
recruiting220%
terminated110%
unknown110%
not_yet_recruiting110%

Recent Activity

Clinical Trials (10)

Drug Details

Intervention Type
DRUG
Total Trials
10